Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. 12:35:27 2024-03-28 pm EDT 5-day change 1st Jan Change
1,918 GBX +2.02% Intraday chart for Hikma Pharmaceuticals PLC +2.40% +7.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data DJ
The FTSE 100 Closed Up 0.4% as U.K. Announces Spring Budget Tax Cuts DJ
Rakuten Medical, Inc. announced that it has received $45 million in funding from Dai-ichi Life Holdings, Inc., Mizuho Bank, Ltd., Hikma Pharmaceuticals PLC, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and another investor CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals MT
AFT Pharmaceuticals Limited Extends License for Maxigesic/Combogesic IV with Hikma Pharmaceuticals CI
RBC Keeps Hikma Pharmaceuticals at Sector Perform, Raises PT MT
Barclays cuts Direct Line to equal weight AN
Stocks called up following slew of FTSE 100 earnings AN
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada MT
Merck's Bridion faces generic threat from drugmaker Hikma RE
Barclays raises Breedon but cuts Domino's Pizza AN
FTSE 100 Closes Up After Nvidia Results Lead to Global Rally DJ
HIKMA PHARMACEUTICALS : Strong Generics-led finish to 2023 Alphavalue
JPMorgan Keeps Hikma Pharmaceuticals at Overweight, Raises PT MT
Transcript : Hikma Pharmaceuticals PLC, 2023 Earnings Call, Feb 22, 2024
Berenberg raises Moneysupermarket.com to 'buy' AN
Hikma boosts dividend after year of "significant progress" AN
Drugmaker Hikma expects profit to be slightly lower in 2024 RE
Hikma Pharmaceuticals Reports Improved FY23 Profit, Revenue MT
Earnings Flash (HIK.L) HIKMA PHARMACEUTICALS Posts FY23 EPS $0.85 MT
Hikma Pharmaceuticals PLC Provides Group Earnings Guidance for the Year 2024 CI
Hikma Pharmaceuticals PLC Announces Board Changes CI
Hikma Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Stocks to rise as Nvidia drives AI optimism AN
Chart Hikma Pharmaceuticals PLC
More charts
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.74 USD
Average target price
29.18 USD
Spread / Average Target
+22.89%
Consensus

Quarterly revenue - Rate of surprise